Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Clinical trial NCT07574541 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07574541
Sponsor: National Cancer Institute (NCI)
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Adenocarcinoma Prostate Cancer Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type

Start date: 2026-08-23
Primary completion: 2027-06-15
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.